14:45:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-27 Kvartalsrapport 2024-Q2
2024-05-24 Kvartalsrapport 2024-Q1
2024-04-26 Ordinarie utdelning DBP B 0.00 SEK
2024-04-25 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-19 Ordinarie utdelning DBP B 0.00 SEK
2023-05-17 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-11-14 Kvartalsrapport 2022-Q3
2022-08-27 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-04-11 Extra Bolagsstämma 2022
2022-04-08 Ordinarie utdelning DBP B 0.00 SEK
2022-04-07 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-04-21 Kvartalsrapport 2021-Q1
2021-04-21 Årsstämma 2021
2021-04-08 Ordinarie utdelning DBP B 0.00 SEK
2021-02-25 Bokslutskommuniké 2020
2020-11-23 Kvartalsrapport 2020-Q3
2020-09-07 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning DBP B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-21 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-09 Ordinarie utdelning DBP B 0.00 SEK
2019-04-08 Årsstämma 2019
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-07 Kvartalsrapport 2018-Q1
2018-04-10 Ordinarie utdelning DBP B 0.00 SEK
2018-04-09 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-09 Ordinarie utdelning DBP B 0.00 SEK
2017-05-08 Årsstämma 2017
2017-05-05 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-05-10 Ordinarie utdelning DBP B 0.00 SEK
2016-05-09 Årsstämma 2016
2016-05-04 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Double Bond Pharmaceutical, DBP, är ett läkemedelsbolag. Störst affärsinriktning innehas mot behandling av cancersjukdomar, infektioner och autoimmuna sjukdomar. Forskningen utgår ifrån bolagets egenutvecklade drug-delivery teknologi. Produkterna säljs under separata varumärken och samarbeten vid produktutveckling sker med andra aktörer inom branschen. Bolaget har sitt huvudkontor i Uppsala.
2021-04-14 10:31:48

Double Bond Pharmaceutical AB (publ) ("DBP") has yesterday hosted an investigators' meeting for the planned SI-053 Phase I study. This is an open label dose escalation and dose expansion study, to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and recommended Phase 2 Dose of SI-053 and the first-patient-in is expected to be enrolled during the second quarter of 2021.

The meeting gathered investigators from 4 clinics in 2 countries together with the Clinical Trial Team from DBP and key personnel from the contract research organization (CRO) CATO-SMS Oncology. The purpose of the meeting was to meet the investigator's and go through the planned SI-053 study in order to ensure that the trial will be conducted in compliance with the Clinical Study Protocol, guidelines and applicable regulations.

The SI-053 study is an open-label dose escalation study to estimate MTD, identify DLTs following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care, in adult patients with newly diagnosed glioblastoma.

"Investigators' meetings are critical for the success of clinical trials and we are incredibly pleased with the interest and engagement that the investigators showed during the meeting. With their valuable insights we can now proceed with finalizing Clinical Study Protocol and proceed with the CTA", comments Breezy Lindqvist, CMO and Director of Clinical Development at DBP.

"We are very pleased to have managed bringing the best expertise in the field of neuro-surgery in EU to clinical development of SI-053 in order to fully explore therapeutic potential of the product,'' - comments Igor Lokot, CEO at DBP.

More about Temodex/SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o